Cytosorbents (CTSO) Gains from Investment Securities (2014 - 2017)
Cytosorbents (CTSO) posted Gains from Investment Securities of -$618248.0 for Q2 2017, down 320.98% on a QoQ basis from -$146858.0 in Q1 2017, and down 424.52% year-over-year from $190513.0 in Q2 2016.
Cytosorbents (CTSO) Gains from Investment Securities (2014 - 2017) Analysis & Trends
Cytosorbents' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$618248.0 for Q2 2017.
- Quarterly Gains from Investment Securities fell 424.52% year-over-year to -$618248.0 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was -$761907.0 (down 283.22% YoY) and the FY2016 annual result came in at $175418.0, up 113.04% from the prior year.
- Gains from Investment Securities was -$618248.0 for Q2 2017 at Cytosorbents, down from -$146858.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.3 million in Q4 2014 and bottomed at -$3.6 million in Q2 2015.
- A 4-year average of $13108.6 and a median of -$82576.0 in 2016 frame the typical range for Gains from Investment Securities.
- Peak annual rise in Gains from Investment Securities reached 735.02% in 2015, while the deepest fall reached 1149.5% in 2015.
- Cytosorbents' Gains from Investment Securities stood at $2.3 million in 2014, then slumped by 122.68% to -$527712.0 in 2015, then climbed by 6.88% to -$491397.0 in 2016, then slipped by 25.81% to -$618248.0 in 2017.
- Business Quant data shows CTSO's Gains from Investment Securities at -$618248.0 in Q2 2017, -$146858.0 in Q1 2017, and -$491397.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.04 Mn | 18.24 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -618,248.00 |
| Jun 30, 2017 | -618,248.00 |
| Mar 31, 2017 | -146,858.00 |
| Mar 31, 2017 | -146,858.00 |
| Dec 31, 2016 | -491,397.00 |
| Dec 31, 2016 | -491,397.00 |
| Sep 30, 2016 | 494,596.00 |
| Sep 30, 2016 | 494,596.00 |
| Jun 30, 2016 | 190,513.00 |
| Jun 30, 2016 | 190,513.00 |
| Mar 31, 2016 | -18,294.00 |
| Mar 31, 2016 | -18,294.00 |
| Dec 31, 2015 | -527,712.00 |
| Dec 31, 2015 | -527,712.00 |
| Sep 30, 2015 | 771,328.00 |
| Sep 30, 2015 | 771,328.00 |
| Jun 30, 2015 | -3.60 Mn |
| Jun 30, 2015 | -3.60 Mn |
| Mar 31, 2015 | 2.01 Mn |
| Mar 31, 2015 | 2.01 Mn |